Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 1/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.34 |
| ▸ | KDM6B | O15054 | 1/20 | 0.31 |
| ▸ | KDM5C | P41229 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5223031 | 0.91 | PSMB8 (0.34) | PSMB8PSMB5KDM6BKDM5CEGLN1 | |
| SCHEMBL2593469 | 0.91 | TSHR (0.37) | PSMB8PSMB5 | |
| SCHEMBL43575 | 0.90 | EGLN1 (0.36) | PSMB8PSMB5KDM6BKDM5CEGLN1 | |
| Ethylene Glycol SCHEMBL2467342 | 0.88 | PSMB8 (0.35) | PSMB8PSMB5KDM6BKDM5CEGLN1 | |
| Methoxymethane SCHEMBL7956362 | 0.85 | EGLN1 (0.37) | PSMB8PSMB5KDM6BKDM5CEGLN1 | |
| Urea SCHEMBL4909809 | 0.84 | PSMB8 (0.34) | PSMB8PSMB5KDM6BKDM5CEGLN1 | |
| Propionic Acid SCHEMBL29510501 | 0.83 | EGLN1 (0.36) | PSMB8PSMB5KDM6BKDM5CEGLN1 | |
| Sulfuric Acid SCHEMBL12813397 | 0.83 | PARL (0.35) | PSMB8PSMB5KDM6BKDM5CEGLN1 | |
| SCHEMBL31121824 | 0.83 | LMNA (0.36) | PSMB8PSMB5KDM6BKDM5CEGLN1 | |
| SCHEMBL2589615 | 0.83 | ALDH1A1 (0.32) | PSMB8PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190263750-A1 | IN VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | THERAGENICS CORPORATION | 2019-08-29 | — | — | US | claimed |
| US-10189773-B2 | In-vivo gelling pharmaceutical pre-formulation | MEDICUS BIOSCIENCES, LLC (US) | 2019-01-29 | — | — | US | claimed |
| EP-2846847-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | Medicus Biosciences LLC (US) | 2015-03-18 | — | — | EP | claimed |
| CN-104428014-A | Biocompatible hydrogel treatment for retinal detachment | MEDICUS BIOSCIENCES LLC | 2015-03-18 | — | — | CN | claimed |
| WO-2013170195-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | MEDICUS BIOSCIENCES, LLC (US) | 2013-11-14 | — | — | WO | claimed |
| US-20130116341-A1 | IN-VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | MEDICUS BIOSCIENCES, LLC (US) | 2013-05-09 | — | — | US | claimed |
| CN-101056595-B | Compositions, systems and methods for treatment of defects in blood vessels | MICROVENTION, INC. (US) | 2012-02-08 | — | — | CN | claimed |
| WO-2011140519-A2 | IN VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | MEDICUS BIOSCIENCES, LLC (US) | 2011-11-10 | — | — | WO | claimed |
| CN-101056595-A | Compositions, systems and methods for treatment of defects in blood vessels | MICROVENTION INC (US) | 2007-10-17 | — | — | CN | claimed |
| EP-1824414-A2 | COMPOSITIONS, SYSTEMS AND METHODS FOR TREATMENT OF DEFECTS IN BLOOD VESSELS | MicroVention, Inc. (US) | 2007-08-29 | — | — | EP | claimed |
| US-7201918-B2 | Compositions, systems and methods for treatment of defects in blood vessels | MICROVENTION, INC. (US) | 2007-04-10 | — | — | US | claimed |
| WO-2006055690-A2 | COMPOSITIONS, SYSTEMS AND METHODS FOR TREATMENT OF DEFECTS IN BLOOD VESSELS | MICROVENTION, INC. (US) | 2006-05-26 | — | — | WO | claimed |
| US-20060105014-A1 | Compositions, systems and methods for treatment of defects in blood vessels | MICROVENTION, INC. (US) | 2006-05-18 | — | — | US | claimed |
| US-20230218799-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | AQUARIAN CREDIT FUNDING LLC | 2023-07-13 | — | — | US | disclosed |
| EP-2968680-B1 | SOLID POLYGLYCOL-BASED BIOCOMPATIBLE PRE-FORMULATION | C P MEDICAL CORP (US) | 2023-05-03 | — | — | EP | disclosed |
| US-11596710-B2 | Biocompatible hydrogel treatments for retinal detachment | AQUARIAN CREDIT FUNDING LLC | 2023-03-07 | — | — | US | disclosed |
| EP-1824414-A2 | COMPOSITIONS, SYSTEMS AND METHODS FOR TREATMENT OF DEFECTS IN BLOOD VESSELS | MicroVention, Inc. (US) | 2007-08-29 | — | — | EP | disclosed |
| US-7201918-B2 | Compositions, systems and methods for treatment of defects in blood vessels | MICROVENTION, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| WO-2006055690-A2 | COMPOSITIONS, SYSTEMS AND METHODS FOR TREATMENT OF DEFECTS IN BLOOD VESSELS | MICROVENTION, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20060105014-A1 | Compositions, systems and methods for treatment of defects in blood vessels | MICROVENTION, INC. (US) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189773-B2 | In-vivo gelling pharmaceutical pre-formulation | FURIN, ARFGAP1, MGST1 | PSMB8 1695/4885PSMB5 2319/4885KDM6B 3872/4885 |
| US-20230218799-A1 | BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT | ALDH1A2, RB1, UACA | PSMB8 2250/4885PSMB5 2255/4885KDM6B 1260/4885 |
| US-11596710-B2 | Biocompatible hydrogel treatments for retinal detachment | ALDH1A2, RB1, UACA | PSMB8 2250/4885PSMB5 2255/4885KDM6B 1260/4885 |
| US-20190263750-A1 | IN VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | FURIN, ARFGAP1, MGST1 | PSMB8 1715/4885PSMB5 2559/4885KDM6B 4054/4885 |
| US-20130116341-A1 | IN-VIVO GELLING PHARMACEUTICAL PRE-FORMULATION | FURIN, ARFGAP1, MGST1 | PSMB8 1695/4885PSMB5 2319/4885KDM6B 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.